Immunovant Inc (NASDAQ:IMVT) shares, rose in value on Thursday, March 27, with the stock price up by 5.03% to the previous day’s close as strong demand from buyers drove the stock to $18.79.
Actively observing the price movement in the last trading, the stock closed the session at $17.89, falling within a range of $17.83 and $18.96. The value of beta (5-year monthly) was 0.676. Referring to stock’s 52-week performance, its high was $34.47, and the low was $17.01. On the whole, IMVT has fluctuated by -6.42% over the past month.
With the market capitalization of Immunovant Inc currently standing at about $3.19 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-29.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IMVT’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of IMVT currently trading nearly -2.43% and -8.58% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.42, while the 7-day volatility ratio is showing 6.22% which for the 30-day chart, stands at 6.60%. Furthermore, Immunovant Inc (IMVT)’s beta value is 0.78, and its average true range (ATR) is 1.22.
A comparison of Immunovant Inc (IMVT) with its peers suggests the former has fared considerably weaker in the market. IMVT showed an intraday change of 5.03% in last session, and over the past year, it shrunk by -39.81%%.
Data on historical trading for Immunovant Inc (NASDAQ:IMVT) indicates that the trading volumes over the past 10 days have averaged 2.65 and over the past 3 months, they’ve averaged 1.46 million. According to company’s latest data on outstanding shares, there are 147.20 million shares outstanding.
Nearly 59.16% of Immunovant Inc’s shares belong to company insiders and institutional investors own 47.38% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 15.8 million shares as on 2025-03-14, resulting in a short ratio of 14.8. According to the data, the short interest in Immunovant Inc (IMVT) stood at 1806.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 14.79 million. The stock has fallen by -24.14% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IMVT stock heading into the next quarter.
